
<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/re.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [
		];
		
	</script>
</head>
<body class="slide-1">

<div id="content">
<div class="blueoverlay"></div>

<header>
<strong>Study 730</strong><br>
KALETRA QD vs BID in na誰ve patients

</header>

<div class="headerborder"></div>
<div class="logo"></div>

<section>

<article>

<p id="first">An open-label, randomized, multicenter, phase 3 study<br>of KALETRA dosed once daily (QD) vs twice daily (BID)<br>+ TDF 300 mg/FTC 200 mg in treatment-na誰ve patients.<sup>2</sup></p>
<p><strong>Primary endpoint</strong></p>
<p class="bullet">Proportion of patients with HIV-1 RNA &lt;50 copies/mL at week 48, (ITT; NC=F) approach comparing QD and BID groups with prespecified non-inferiority margin: 12%.</p>
<div class="bluepanel">
    <p><strong>Results and Virologic Failures</strong></p>
    <p class="bullet">At week 48, 77% of QD-dosed patients vs 76% of BID-<br>dosed patients had HIV-1 RNA &lt;50 copies/mL (<em>P</em>=0.715).</p>
    <p class="bullet">10% of patients in the QD group and 8% of patients <br>in the BID group experienced virologic failure through <br>week 48 (includes confirmed viral rebound and failure <br>to achieve &lt;50 copies/mL). </p>
</div>

<p><strong>Once-daily dosing considerations</strong></p>
<p class="bullet">Do not administer once-daily KALETRA in pediatric patients; in adult patients with three or more lopinavir resistance substitutions; or in combination with efavirenz, nevirapine, nelfinavir, carbamazepine, phenobarbital, or phenytoin.</p>
<p class="bullet">Patients should be informed that there may be greater chance of developing diarrhea  with the once-daily<br>regimen as compared with the twice-daily regimen.</p>
</article>

<aside>

<div class="asidehead">
<strong>Study 720</strong><br>
7-year Open-Label Extension (OLE)<br>KALETRA study in ARV-na誰ve patients 

</div>

<div class="border"></div>

<p id="first1">A phase 2, dose-ranging, randomized, multicenter<br>trial evaluating the safety and efficacy of KALETRA<br>soft-gel capsules with stavudine and lamivudine at<br>3 dose levels within 2 groups of treatment-na誰ve<br>patients with confirmed HIV-1 infection. The study<br>consisted of a double-blind study period and an<br>open-label study period (n=100).<sup>3</sup></p>
<p><strong>Primary endpoint</p>
<p class="bullet">Proportion of patients with plasma HIV-1 RNA<br>&lt;400 copies/mL or &lt;50 copies/mL at week 24 and <br>the duration of virologic response through week 48.</p>
<p class="bullet">The study was extended with an open-label follow-up period through 360 weeks.</p>

<div class="bluepanel">
    <p><strong>Results and Adverse Events</strong></p>
    <p class="bullet">At 7 years, by ITT analysis, 61% had plasma HIV-1 RNA &lt;400 copies/mL and 59% had &lt;50 copies/mL.</p>
    <p class="bullet">In KALETRA clinical trials, the most common adverse reactions reported in &gt;5% of adult patients were diarrhea, nausea, abdominal pain, asthenia, vomiting, headache, and dyspepsia. In Study 720, lipodystrophy was also reported.
   </p>
</div>

<p class="smtext">KALETRA, lopinavir/ritonavir; TDF, tenofovir; FTC, emtricitabine;<br>ITT, intent to treat; NC=F, non-completer equals failure.</p>



</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('re-01-popup-02','730Study Design','<table width=\'680px\'><tr align=\'center\'><td class=\'reference\'>730 Study Design<sup>2</sup></td></tr></table>','90','633','10','0','680','545','1','0','1','0'));">730<br>Study Design</button>
    <button onclick="makecall('PopupWithHeader',Array('re-01-popup-01','720Study Design','<table width=\'970px\'><tr align=\'center\'><td class=\'reference\'>720 Study Design<sup>3</sup></td></tr></table>','230','633','10','0','970','450','1','0','1','0'));">720<br>Study Design</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>



</div>
</body>
</html>